A top Gilead exec told us the story behind the biotech’s unusual $5.1 billion deal that’s the exact opposite of a Big Pharma trend
|07/16/2019||Posted by BusinessMediaguide.Com under General World News||
- The biopharmaceutical company Gilead just struck a $5.1 billion partnership with the Belgian biotech Galapagos that helps boost its pipeline of experimental drugs.
- The deal dates back to a casual meeting in January, with six months of negotiations following under the codename “Project Eagles,” Gilead exec Andrew Dickinson told Business Insider.
- The agreement was finalized the night of a big party held to celebrate Galapagos’s 20th anniversary, he said.
- In an age of pharma mega-deals, such a big-ticket partnership is relatively unusual — and it was difficult to execute, Dickinson told us.
- Click here for more BI Prime stories.
The read more >>>